TELA Bio, Inc. (TELA)

Market Cap	40.20M -36.2%
Revenue (ttm)	79.91M +6.1%
Net Income	-41.18M
EPS	-0.78
Shares Out	45.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	229,010
Open	0.8300
Previous Close	0.8301
Day's Range	0.8300 - 0.9400
52-Week Range	0.5011 - 1.7270
Beta	1.36
Analysts	Buy
Price Target	2.10 (+135.82%)
Earnings Date	Aug 10, 2026

About TELA

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 8, 2019
• Employees: 218
• Stock Exchange: NASDAQ
• Ticker Symbol: TELA
• Website: https://www.telabio.com

Financial Performance

In 2025, TELA Bio's revenue was $80.28 million, an increase of 15.84% compared to the previous year's $69.30 million. Losses were -$38.83 million, 2.62% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for TELA stock is "Buy." The 12-month stock price target is $2.1, which is an increase of 135.82% from the latest price.

Price Target

$2.1

(135.82% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 9, 2026

Data Sources Report a data error